Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E21.80 EPS (ttm)4.29 Insider Own0.09% Shs Outstand1.52B Perf Week-2.04%
Market Cap142.11B Forward P/E10.49 EPS next Y8.91 Insider Trans-3.09% Shs Float1.51B Perf Month-3.84%
Income6.82B PEG1.34 EPS next Q2.01 Inst Own71.60% Short Float2.08% Perf Quarter0.40%
Sales30.95B P/S4.59 EPS this Y-2.40% Inst Trans-4.39% Short Ratio5.41 Perf Half Y-1.95%
Book/sh-2.15 P/B- EPS next Y13.23% ROA9.50% Target Price109.45 Perf Year6.79%
Cash/sh2.46 P/C37.97 EPS next 5Y16.32% ROE214.60% 52W Range83.19 - 125.86 Perf YTD-3.40%
Dividend3.84 P/FCF23.29 EPS past 5Y1.20% ROI17.80% 52W High-25.77% Beta1.54
Dividend %4.11% Quick Ratio0.70 Sales past 5Y9.00% Gross Margin75.80% 52W Low12.30% ATR1.88
Employees29000 Current Ratio0.80 Sales Q/Q19.20% Oper. Margin32.80% RSI (14)46.39 Volatility2.47% 1.89%
OptionableYes Debt/Eq- EPS Q/Q5.40% Profit Margin20.70% Rel Volume1.01 Prev Close92.26
ShortableYes LT Debt/Eq- EarningsNov 02 BMO Payout72.90% Avg Volume5.81M Price93.42
Recom2.40 SMA20-1.50% SMA50-1.45% SMA200-7.06% Volume5,864,982 Change1.26%
Jun-01-18Downgrade Piper Jaffray Overweight → Neutral
May-30-18Downgrade Credit Suisse Neutral → Underperform
Jan-30-18Reiterated Morgan Stanley Equal-Weight $99 → $131
Jan-29-18Downgrade Leerink Partners Outperform → Mkt Perform
Oct-30-17Reiterated Leerink Partners Outperform $108 → $107
Oct-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Sep-25-17Downgrade UBS Buy → Neutral $79 → $92
Aug-17-17Initiated Evercore ISI Outperform $95
Jun-22-17Upgrade Societe Generale Hold → Buy
Mar-22-17Upgrade Societe Generale Sell → Hold
Oct-31-16Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-24-18 08:00PM  Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against AbbVie Inc. (ABBV) GlobeNewswire
04:33PM  Hagens Berman Alerts Investors in AbbVie Inc. (NYSE: ABBV) to the November 20, 2018 Securities Class Action Lead Plaintiff Deadline GlobeNewswire
03:58PM  CLASS ACTION ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Significant Losses From Investment In AbbVie Inc. (NYSE: ABBV) To Contact Brower Piven Before The Lead Plaintiff Deadline GlobeNewswire
02:58PM  ABBVIE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $500,000 Investing In AbbVie Inc. To Contact The Firm PR Newswire
11:54AM  IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
10:25AM  AbbVie/Roche's Leukemia Drugs Combo Gets CHMP Backing in EU Zacks
07:00AM  AbbVie Class Action: Bernstein Liebhard LLP Announces That a Securities Class Action Lawsuit Has Been Filed Against AbbVie Inc - ABBV GlobeNewswire
Sep-23-18 11:00AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TRCO, COCP and ABBV GlobeNewswire
10:28AM  AbbVie Class Action: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against AbbVie Inc. - ABBV PR Newswire
Sep-22-18 12:35AM  U.S. Probes Drugmakers Over Free Services The Wall Street Journal
Sep-21-18 11:33PM  EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against AbbVie Inc. ABBV Business Wire
05:45PM  AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know Zacks
05:05PM  Hagens Berman Alerts Investors in AbbVie Inc. (ABBV) to the Firm's Investigation of Possible Humira-Related Health Insurance Fraud and Disclosure Violations PR Newswire
03:23PM  U.S. Probes Drugmakers Over Free Services The Wall Street Journal
03:18PM  CLASS ACTION UPDATE for AMPE, COCP, ABBV and SKX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
02:12PM  INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
11:05AM  AbbVie Investigation: Bernstein Liebhard LLP Announces Investigation of AbbVie Inc. - ABBV GlobeNewswire
10:19AM  CRON Stock Is a Long-term Play With Near-Term Challenges InvestorPlace
09:24AM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against AbbVie Inc. ABBV Business Wire
07:27AM  AbbVie Receives Positive CHMP Opinion for a Novel, Chemotherapy-free Combination of VENCLYXTO® (venetoclax tablets) with Rituximab as a Treatment with a Fixed Duration for Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy PR Newswire
12:00AM  How Do Drugs Compete Against Each Other? Motley Fool
Sep-20-18 07:08PM  ABBV INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of AbbVie Inc. Investors Business Wire
05:27PM  SHAREHOLDER ALERT: ZN RMTI TTPH ABBV HMNY GDS PVG OPK USAT TRCO: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
02:13PM  AbbVie Investigation: Bernstein Liebhard LLP Announces Investigation Of AbbVie Inc. - ABBV PR Newswire
09:56AM  Company News For Sep 20, 2018 Zacks
05:07AM  EU approves fifth copy of AbbVie's $18 billion drug Humira Reuters
05:02AM  EU approves fifth copy of AbbVie's $18 bln drug Humira Reuters
04:00AM  Mylan, Fujifilm win EU okay for copy of AbbVie's Humira Reuters
Sep-19-18 11:04AM  AbbVie Faces California Insurance Department Suit for Humira Zacks
10:14AM  AbbVie shares fall after being sued over Humira allegations American City Business Journals
09:58AM  Investor Alert: Kaplan Fox Investigates AbbVie Inc. PR Newswire
08:31AM  3 Big Stock Charts for Wednesday: DISH Network, BorgWarner and Procter & Gamble InvestorPlace
08:08AM  Stocks making the biggest move premarket: TSLA, TLRY, NFLX, ABBV & more CNBC
Sep-18-18 06:54PM  AbbVie Falls 3.03% Investing.com
06:08PM  California: Drugmaker paid doctors to overprescribe Humira Associated Press
05:33PM  After-hours buzz: TLRY, FIT & more CNBC
03:18PM  California insurance regulator sues AbbVie alleging Humira kickbacks Reuters
02:52PM  AbbVie stock drops 2% after California lawsuit alleges illegal activity used to push blockbuster drug MarketWatch
02:51PM  California insurance commissioner sues AbbVie over Humira Reuters
02:23PM  AbbVie shares fall after California insurance regulator sues company over alleged kickbacks CNBC
02:21PM  California insurance department sues Abbvie over alleged ... CNBC Videos
02:01PM  California Sues AbbVie Over Alleged Arthritis Drug Kickbacks Bloomberg
12:59PM  15 Best S&P 500 Stocks to Buy as the Markets Heat Up InvestorPlace
07:38AM  New local Ronald McDonald House set for construction American City Business Journals
06:32AM  3 Top Healthcare Stocks to Buy Right Now Motley Fool
06:01AM  Is Galapagos NV a Buy Now? Motley Fool
Sep-17-18 02:33PM  Why Gilead Stock Is a Sleepy Giant Waiting to Break Out InvestorPlace
10:01AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline - September 24, 2018 ACCESSWIRE
08:59AM  The Zacks Analyst Blog Highlights: JPMorgan, Mastercard, AbbVie, CVS Health and Estee Lauder Zacks
08:00AM  AbbVie to Host Third-Quarter 2018 Earnings Conference Call PR Newswire
Sep-14-18 10:52AM  Top Stock Reports for JPMorgan, Mastercard & AbbVie Zacks
09:43AM  Pharma/Biotech Stocks to Watch This Prostate Cancer Month Zacks
09:29AM  Roche's Child Arthritis Drug's New Formulation Gets FDA Nod Zacks
08:16AM  3 Things You Might Be Overlooking With AbbVie Motley Fool
08:00AM  Todays Research Reports on Stocks to Watch: AbbVie and Progenics Pharmaceuticals ACCESSWIRE
06:15AM  A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis Motley Fool
Sep-13-18 04:38PM  AbbVie Rises 3.02% Investing.com
10:46AM  AbbVie Inc. -- Moody's assigns Baa2 to AbbVie's sr. notes; stable outlook Moody's
09:30AM  Should Value Investors Consider AbbVie (ABBV) Stock Now? Zacks
09:20AM  AbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient-Reported Outcomes Data from Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology (EADV) Congress PR Newswire
06:20AM  AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis PR Newswire
Sep-12-18 02:57PM  5 Growth Stocks to Buy for Reliable Income in Retirement InvestorPlace
02:36PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FIZZ, RMTI, TTPH, ABBV and GDS GlobeNewswire
10:26AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline September 24, 2018 ACCESSWIRE
09:50AM  AbbVie Gets FDA Nod for Venclexta Label Expansion in Leukemia Zacks
Sep-11-18 08:17AM  Minimal Residual Disease Negativity Data, a Measure of Undetectable Disease, Added to VENCLEXTA® (venetoclax tablets) Label PR Newswire
Sep-09-18 01:00PM  CLASS ACTION UPDATE for RMTI, ABBV and HMNY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Sep-07-18 02:37PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ACAD, ABBV and FB GlobeNewswire
11:23AM  AbbVie Declares Quarterly Dividend PR Newswire
10:45AM  Vertex Completes Enrollment in Triple Combination Studies Zacks
08:58AM  Lilly, Teva, Pfizer & Others Await FDA Decisions in September Zacks
07:37AM  Jim Cramer Weighs In On CarMax, AbbVie And More Benzinga
Sep-06-18 06:30AM  3 Top Big Pharma Stocks to Buy Now Motley Fool
Sep-05-18 06:50PM  Top 5 Biotech Stocks for 2018 Investopedia
12:37PM  SHAREHOLDER ALERT: TSLA LOGM GLCNF ACAD MD FPI RMTI ABBV GDS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
10:56AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against AbbVie Inc. (ABBV) and Lead Plaintiff Deadline September 24, 2018 ACCESSWIRE
Sep-04-18 09:00AM  AbbVie Reinforces Leadership in Dermatology With New Data Showcasing Research Advancements Across Growing Portfolio at the 27th European Academy of Dermatology and Venereology (EADV) Congress PR Newswire
08:00AM  Is Now a Good Time to Buy Gilead Sciences? Motley Fool
Sep-02-18 12:00AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MD, ACAD, RMTI and ABBV GlobeNewswire
Aug-31-18 01:29PM  Do the Risks in Marijuana Stocks Outweigh the Rewards? InvestorPlace
10:19AM  Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus Zacks
08:39AM  4 Large Cap Pharma Stocks in Focus on Robust Cancer Pipeline Zacks
Aug-29-18 05:06PM  CLASS ACTION UPDATE for MD and ABBV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:00AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) and Lead Plaintiff Deadline September 24, 2018 GlobeNewswire
09:35AM  Europe ready to cash in on cheap copies of AbbVie biotech drug Reuters
09:15AM  FOCUS-Europe ready to cash in on cheap copies of AbbVie biotech drug Reuters
Aug-28-18 05:45PM  AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know Zacks
10:42AM  AbbVie's Imbruvica Combo Gets FDA Nod for Rare Lymphoma Zacks
10:25AM  Biotech Stocks Take Aim At New Highs In August 2018 ACCESSWIRE
08:00AM  AbbVie to Present at the Morgan Stanley 16th Annual Global Healthcare Conference PR Newswire
Aug-27-18 06:03PM  AbbVie's Imbruvica Approved for Type of Non-Hodgkin Lymphoma GuruFocus.com
09:38AM  AbbVie's Rare Blood Cancer Drug Combo Snags FDA Approval Benzinga
08:47AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
08:00AM  Today's Research Reports on Trending Tickers: AbbVie and Merck & Co. ACCESSWIRE
07:00AM  AbbVie Announces IMBRUVICA® (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström's Macroglobulinemia, a Rare Type of Blood Cancer PR Newswire
Aug-26-18 11:50AM  Edited Transcript of ABBV earnings conference call or presentation 27-Jul-18 1:00pm GMT Thomson Reuters StreetEvents
09:16AM  3 Dividend Stocks to Buy on Sale Motley Fool
Aug-25-18 12:00PM  3 Top Value Stocks to Buy in August Motley Fool
09:26AM  The AbbVie Inc (NYSE:ABBV) Ownership Structure Could Be Important Simply Wall St.
07:20AM  Better Buy: AbbVie Inc. vs. Merck & Co., Inc. Motley Fool
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection for autoimmune diseases; IMBRUVICA, an oral therapy for patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. It serves wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has collaboration with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; International Myeloma Foundation; Calibr and Scripps Research; The Institute for Research in Immunology and Cancer ? Commercialization of Research; the Universite de Montreal; and Tolero Pharmaceuticals, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SEVERINO MICHAELEVP, R&D and CSOAug 17Sale97.5250,0004,876,06082,281Aug 21 04:58 PM
TILTON GLENN FDirectorJun 27Buy91.905,400496,27439,735Jun 29 02:30 PM
RAPP EDWARD JDirectorJun 20Buy98.631,01399,90920,743Jun 22 05:56 PM
ALBAN CARLOSEVP, Commercial OperationsMar 01Option Exercise29.2348,1001,405,795178,547Mar 02 05:29 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMar 01Option Exercise25.9132,400839,339197,263Mar 02 05:28 PM
ALBAN CARLOSEVP, Commercial OperationsMar 01Sale114.3980,9959,264,80897,552Mar 02 05:29 PM
Schumacher Laura JExecutive Vice PresidentMar 01Sale117.8525,0002,946,14898,317Mar 02 05:28 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMar 01Sale114.5032,4003,709,687164,863Mar 02 05:28 PM
Michael Robert A.VP, ControllerFeb 28Sale119.434,294512,8536,876Mar 02 05:31 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 28Sale117.771,337157,45893,312Mar 02 05:31 PM
SEVERINO MICHAELEVP, R&D and CSOFeb 28Sale117.932,643311,684132,281Mar 02 05:30 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 28Sale118.6718,1292,151,45217,588Mar 02 05:30 PM
CHASE WILLIAM JEVP, Chief Financial OfficerFeb 28Sale119.4438,5284,601,954164,863Mar 02 05:28 PM
ALBAN CARLOSEVP, Commercial OperationsFeb 28Sale117.852,579303,928130,447Mar 02 05:29 PM
GONZALEZ RICHARD AChairman of the Board and CEOFeb 28Sale117.888,280976,084313,012Mar 02 05:28 PM
Michael Robert A.VP, ControllerFeb 20Sale120.31992119,35113,557Feb 20 06:08 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesDec 18Option Exercise35.8887,0403,122,995113,118Dec 19 06:09 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesDec 18Sale98.4587,0408,569,05326,078Dec 19 06:09 PM
Schumacher Laura JExecutive Vice PresidentDec 15Option Exercise35.881,14341,011106,875Dec 15 05:13 PM
Schumacher Laura JExecutive Vice PresidentDec 14Option Exercise35.88144,3675,179,888250,099Dec 15 05:13 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 21Option Exercise58.88218,19312,847,204492,030Nov 24 04:55 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 21Sale94.01218,19320,511,800273,837Nov 24 04:55 PM
SEVERINO MICHAELEVP, R&D and CSONov 10Sale94.6925,6332,427,212114,922Nov 13 05:26 PM
Gosebruch Henry OChief Strategy OfficerOct 30Sale90.5518,3001,657,03765,137Oct 31 05:04 PM
Michael Robert A.VP, ControllerSep 28Sale88.006,699589,51210,007Sep 29 05:02 PM